Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Trastuzumab in patients with Esophagogastric Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with 5-fluorouracil and cisplatin (21 days) as a treatment option for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.